BRAFV600E-dependent Mcl-1 stabilization leads to everolimus resistance in colon cancer cells

mTOR activation is commonly caused by oncogenic mutations in RAS/RAF/MAPK and PI3K/AKT pathways, and promotes cancer progression and therapeutic resistance. However, mTOR inhibitors show limited single agent efficacy in patients. mTOR inhibitors suppress tumor cell growth and angiogenesis, and have...

Descripción completa

Detalles Bibliográficos
Autores principales: He, Kan, Chen, Dongshi, Ruan, Hang, Li, Xiangyun, Tong, Jingshan, Xu, Xiang, Zhang, Lin, Yu, Jian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5216972/
https://www.ncbi.nlm.nih.gov/pubmed/27351224
http://dx.doi.org/10.18632/oncotarget.10277

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5216972/
https://www.ncbi.nlm.nih.gov/pubmed/27351224
http://dx.doi.org/10.18632/oncotarget.10277

Ejemplares similares